Hudson Bay Capital Management LP Acquires 34,810 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Hudson Bay Capital Management LP raised its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 98.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 70,319 shares of the biotechnology company's stock after purchasing an additional 34,810 shares during the quarter. Hudson Bay Capital Management LP owned 0.16% of United Therapeutics worth $24,811,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in the business. Wealthfront Advisers LLC raised its position in United Therapeutics by 2,090,573.5% in the fourth quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company's stock worth $6,462,018,000 after acquiring an additional 18,313,424 shares during the period. Vanguard Group Inc. lifted its stake in United Therapeutics by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 4,441,823 shares of the biotechnology company's stock valued at $1,567,253,000 after purchasing an additional 32,213 shares during the last quarter. FMR LLC grew its holdings in United Therapeutics by 36.5% during the fourth quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company's stock valued at $519,170,000 after purchasing an additional 393,777 shares during the period. Geode Capital Management LLC increased its position in United Therapeutics by 4.0% in the fourth quarter. Geode Capital Management LLC now owns 1,138,292 shares of the biotechnology company's stock worth $401,184,000 after buying an additional 44,277 shares during the last quarter. Finally, AQR Capital Management LLC raised its stake in shares of United Therapeutics by 0.8% in the fourth quarter. AQR Capital Management LLC now owns 975,444 shares of the biotechnology company's stock valued at $344,176,000 after buying an additional 7,710 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Price Performance

Shares of UTHR opened at $301.42 on Friday. United Therapeutics Co. has a 1-year low of $263.56 and a 1-year high of $417.82. The company has a market capitalization of $13.60 billion, a P/E ratio of 13.24, a P/E/G ratio of 0.97 and a beta of 0.58. The firm's 50 day simple moving average is $300.53 and its 200 day simple moving average is $342.07.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $794.40 million during the quarter, compared to the consensus estimate of $726.82 million. During the same period in the previous year, the firm posted $6.17 EPS. The firm's revenue was up 17.2% compared to the same quarter last year. On average, equities analysts anticipate that United Therapeutics Co. will post 24.48 earnings per share for the current year.

Insider Activity at United Therapeutics

In other news, COO Michael Benkowitz sold 10,000 shares of the firm's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $371.05, for a total transaction of $3,710,500.00. Following the transaction, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at approximately $956,195.85. This trade represents a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction dated Thursday, April 3rd. The stock was sold at an average price of $306.18, for a total value of $3,367,980.00. Following the completion of the transaction, the executive vice president now owns 36,781 shares in the company, valued at approximately $11,261,606.58. This represents a 23.02 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 75,500 shares of company stock valued at $24,245,880. Corporate insiders own 11.90% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on UTHR. StockNews.com lowered United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. JPMorgan Chase & Co. dropped their price target on shares of United Therapeutics from $355.00 to $350.00 and set an "overweight" rating on the stock in a research note on Thursday, May 1st. Bank of America raised shares of United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 price objective for the company in a report on Monday, April 21st. Morgan Stanley boosted their target price on shares of United Therapeutics from $346.00 to $348.00 and gave the company an "equal weight" rating in a report on Thursday, May 1st. Finally, Wells Fargo & Company reaffirmed an "equal weight" rating and issued a $314.00 price target (down from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. Four equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $392.00.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.